Pfizer Profile 1007 study meets primary endpoint
03:50 EDT 20 Jun 2012 | Pharmaceutical Business Review
Pfizer has announced positive results from Phase 3 Profile 1007 study evaluating Xalkori (crizotinib) in patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who were previously treated.
Original Article: Pfizer Profile 1007 study meets primary endpoint
More From BioPortfolio on "Pfizer Profile 1007 study meets primary endpoint"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
